A sector briefing from Catalent and industry analysts highlighted the acute complexity of cell and gene therapy (CGT) supply chains—ranging from collection and chain‑of‑identity to manufacturing, temperature control and rapid delivery to patients. The piece outlined operational risks and the value of specialized external partners. CGT supply chains are time‑sensitive and highly regulated; Catalent argued that experienced logistics, robust data exchange and contingency planning are essential to preserve product viability. The analysis stressed regulatory compliance, documentation standards, and the need for scalable infrastructure as more CGTs move toward commercialization. The article framed supply‑chain readiness as a gating factor for patient access and program success, especially for autologous and in‑vivo modalities.